Computerised counting of tumour infiltrating lymphocytes in 90 breast cancer specimens

Cancer Letters

Volumn 139, Issue 1, 1999, Pages 33-41

  Marsigliante, S ^a   Biscozzo, L ^b   Marra, A ^a   Nicolardi, G ^a   Leo, G ^b   Lobreglio, G B ^b   Storelli, C ^a  

^a UNIVERSITY OF SALENTO   (Italy)

^b VITO FAZZI HOSPITAL   (Italy)

Author keywords

Breast cancer; CD; Lymphocytes

Indexed keywords

CD20 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; INTERLEUKIN 2 RECEPTOR;

ANTIGEN EXPRESSION; ARTICLE; AUTOANALYSIS; BREAST CANCER; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TUMOR ASSOCIATED LEUKOCYTE;

ADULT; AGE FACTORS; AGED; ANIMALS; ANTIGENS, CD3; ANTIGENS, CD4; ANTIGENS, CD8; BREAST NEOPLASMS; FEMALE; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; LYMPHOCYTES, TUMOR-INFILTRATING; MIDDLE AGED;

EID: 0032902729     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(98)00379-6     Document Type: Article

References (22)

1. Alderson M.R., Hamlin I., Staunton M.D. The relative significance of prognostic factors in breast carcinoma. Br. J. Cancer. 25:1971;646-656.
2. Atkins M.B., Gould J.A., Allegretta M., Li J.J., Dempsey R.A., Rudders R.A., Parkinson D.R., Reichlin S., Mier J. Phase I evaluation of recombinant IL-2 in patient with advanced malignant disease. J. Clin. Oncol. 4:1986;1380-1391.
3. Bhan A.K., Desmarais C.L. Immunohistologic characterization of major histocompatibility antigens and inflammatory cellular infiltrate in human breast cancer. J. Natl. Cancer. 71:1983;507.
4. Bilik R., Mor C., Hazaz B., Moroz C. Characterization of T-lymphocyte subpopulations infiltrating primary breast cancer. Cancer Immunol. Immun. 28:1989;143-147.
5. Bloom H.J.G., Richardson W.W. Histological grading and prognosis in breast cancer. Br. J. Cancer. 11:1957;359-377.
6. Chin Y., Janseens J., Vandepitte J., Vandenbrande J., Opdebeek L., Raus J. Phenotypic analysis of tumor-infiltrating lymphocytes from human breast cancer. Anticancer Res. 12:1992;1463-1466.
7. Eremin O., Coombs R.R.A., Ashby J. Lymphocytes infiltrating human breast cancer lack K-cell activity and show low level of NK-cell activity. Br. J. Cancer. 44:1981;166-171.
8. Gause B.L., Sznol M., Kopp W.C., Janik J.E., Smith J.W., Steis R.G., Urba W.J., Sharfman W., Fenton R.G., Creekmore S.P., Holmlund J., Conlon K.C., Vandermolen L.A., Longo D.L. Phase I study of subcutaneously administered Interleukin 2 in combination with Interferon a 2A in patient with advanced cancer. J. Clin. Oncol. 14:1996;2234-2241.
9. Gharib M., Mainguene C., Tamboise E., Tamboise A., Lievre N., Amouroux J., Beaupain R. Effect of LAK cells activated by IL-2 on MCF-7 human breast cancer cell lines maintained in organotypic culture. Cancer. 80:1993;659-665.
10. Hank J.A., Kohler P.C., Weil-Hillman G., Rosenthal N., Moore K.H., Storer B., Minkoff D., Bradshaw J., Bechhofer R., Sondel P.M. In vivo induction of the lymphokine-activated killer phenomenon: Interleukin 2-dependent human non-major histocompatibility complex-restricted cytotoxicity generated in vivo during administration of human recombinant interleukin-2. Cancer Res. 48:1988;1965-1971.
11. Hillman-Weil G., Voss S.D., Fisch P., Schell K., Hank J.A., Sosman J.A., Sugamura K., Sondel P.M. Natural killer cells activated by interleukin 2 treatment in vivo respond to interleukin 2 primarily through the p75 receptors and maintain the p55 (TAC) negative phenotype. Cancer Res. 50:1990;2683-2691.
12. Introna A., Allavena P., Biondi A., Colombo N., Villa N., Mantovani A. Defective natural killer activity within human ovarian tumors: low numbers of morphologically defined effectors present in situ. J. Natl. Cancer Inst. 70:1983;21-26.
13. Marrogi A.J., Munshi A., Merogi A.J., Ohadike Y., El-Habashi A., Marrogi O.L., Freeman S.M. Study of tumor infiltrating lymphocytes and transforming growth factor-beta as prognostic factors in breast carcinoma. Int. J. Cancer. 74:1997;492-501.
14. Moy P.M., Holmes E.C., Golub S.H. Depression of natural killer cytotoxic activity in lymphocytes infiltrating human pulmonary tumors. Cancer Res. 45:1985;57-62.
15. Parl F.F., Dupont W.D. A retrospective cohort study of histologic risk factors in breast cancer patients. Cancer. 50:1982;2410-2416.
16. Peuchmaur M., Emilie D., Crevon M.C., Brousse N., Gaulard P., D'Agay M.F., Galanaud P., Solal-Celigny P. Interleukin-2 and interferon-γ production in follicular lymphomas. Am. J. Clin. Pathol. 95:1991;55-62.
17. Rilke F., Colnaghi M.I., Cascinelli N., Andreola S., Baldini M.T., Bufalino R., Della Porta G., Menard S., Pierotti M.A., Testori A. Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factor. Int. J. Cancer. 49:1991;44-49.
18. Roses D.F., Bell D.A., Flotte T.J., Taylor R., Ratech H., Dubin N. Pathologic predictors of recurrence in stage I breast cancer. Am. J. Clin. Pathol. 78:1982;817-820.
19. Sondel P.M., Kohler P.C., Hank J.A., Moore K.H., Rosenthal N.S., Sosman J.A., Bechhofer R., Storer B. Clinical and immunological effects of recombinant Interleukin-2 given by repetitive weekly cycle to patients with cancer. Cancer Res. 48:1988;2561-2567.
20. Tötterman T.H., Parthenais E., Häyry P., Timonen T., Saksela E. Cytological and functional analysis of inflammatory infiltrates in human malignant tumors. III. Further functional investigation using cultured autochthonous tumor cell lines and freeze-thawed infiltrating inflammatory cells. Cell Immunol. 55:1980;219-224.
21. Underwood J.C. Lymphoreticular infiltration in human tumors: prognostic and biological implications: a review. Br. J. Cancer. 30:1974;538-547.
22. Vose B.M., Vanky F., Klein E. Human tumor-lymphocyte interaction in vitro. V. Comparison of the reactivity of tumor-infiltrating, blood and lymph-node lymphocytes with autologous tumors cells. Int. J. Cancer. 20:1977;895-899.